The Top 5 Biosimilars Articles for the Week of June 4

The Center for Biosimilars® recaps the top 5 articles for the week of June 4, 2018.
June 08, 2018



Transcript:

Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of June 4.

Number 5: Mylan and its partner Biocon received a Complete Response Letter from the FDA for their follow-on insulin glargine referencing Lantus.

Number 4: Celltrion has reported positive results of a study of a subcutaneous formulation of its biosimilar infliximab, Inflectra, in patients with Crohn disease.

Number 3: The FDA published new draft guidance that clarifies the types of formal meetings that biosimilar applicants can hold with the agency.

Number 2: During the 2018 American Society of Clinical Oncology Annual Meeting, researchers presented on new directions in anticancer and supportive care biosimilars.

Number 1: The FDA has approved its first pegfilgrastim biosimilar, Fulphila, referencing Neulasta.

Finally, last week, our e-newsletter asked whether you that US payers should encourage greater use of biosimilars.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.
 

x-button

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2018 Intellisphere, LLC. All Rights Reserved.